Cargando…
PB2107: EVOLUTION OF SELECTION CRITERIA FOR PHASE 3 CLINICAL TRIALS IN MULTIPLE MYELOMA.
Autores principales: | Pérez, Ernesto, Muñagorri, Idoa Múgica, Garcia, Adrian Casamayor, Esteban, Jorge Illarramendi, Limas, Diana Gisell Gabaldón |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429098/ http://dx.doi.org/10.1097/01.HS9.0000975212.50917.97 |
Ejemplares similares
-
PB2107: CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA
por: Liu, J., et al.
Publicado: (2022) -
PB2126: RETROSPECTIVE REAL LIFE STUDY OF MULTIPLE MYELOMA STATUS AT DEATH.
por: Pérez, Mónica Fernández, et al.
Publicado: (2023) -
PB2123: ROLE OF INTERLEUKIN 6 AND ANGIOPOIETINS 1 AND 2 IN THE EVOLUTION OF PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA
por: Upegui, Rosa Isabel, et al.
Publicado: (2023) -
PB2157: AUTOSCT IN PATIENTS WITH MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT NEPHROPATHY
por: Karimova, Ekaterina, et al.
Publicado: (2023) -
PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)